Eli Lilly to invest $5.3B more to boost weight-loss drug production, WSJ reports

Eli Lilly is expected to announce Friday that it will spend $5.3B to boost manufacturing capacity for its anti-obesity drug Zepbound and cousin diabetes drug Mounjaro, according to The Wall Street Journal’s Peter Loftus. Lilly will significantly expand a production site that is under construction on 600 acres in Lebanon, Indiana and together with funding that it previously committed, Lilly will spend $9B total on the new site, which The Journal calls “the largest manufacturing investment in its history.”